news
bit.bio raises $103 million in first close of Series B financing
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
List view / Grid view
Charles River Laboratories
news
Cell-based assays market set to exhibit CAGR of 8.5 percent
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
article
Under the microscope: CROs and microplate reader requirements
Contract Research Organisations rely on microplate readers for effective hit discovery. Ian Waddell, of Charles River Laboratories, explains what his needs are.
news
Charles River Laboratories continues commitment to oncology drug discovery
Team of oncology experts expand data in Tumor Model Compendium and present strong portfolio at industry conferences...
news
Charles River to present collaborative methods at Neuroscience 2018
Charles River Laboratories International, Inc. (NYSE: CRL) announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN)...
news
Charles River and Distributed Bio enter exclusive partnership to create an integrated antibody discovery and development platform
Charles River Laboratories International, Inc. announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimisation of antibody discovery platforms...
news
Charles River Laboratories announces extended relationship with The Michael J. Fox Foundation
Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research.
news
Charles River Laboratories expands services for early discovery screening
Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery.
webinar
Biomarker endpoints for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.
webinar
in vitro phenotypic assays for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar highlights cell based assays for Parkinson’s disease that include endpoints such as a-synuclein aggregation and mitophagy readouts.
news
Charles River Laboratories announces new tumour model compendium
The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies.
news
Charles River Laboratories makes investments in high-throughput screening infrastructure
Signs collaboration agreement with AstraZeneca to offer state-of-the-art technology to clients.
webinar
Using open science to develop Pediatric Cancer Drugs
2 January 2018 | By Charles River Laboratories
The webinar speakers highlight the collaboration between patient groups, charities, and academia led to the development of inhibitors targeting gliomas.
article
Q&A: Integrated drug discovery panel – your questions answered
Drug discovery from concept to drug candidate has become a collective effort where multi-disciplinary project teams from CROs work with drug companies and academia to deliver clinical candidates, overcoming multi-factorial research obstacles along the way.
news
Charles River adds ERS License to CRISPR/Cas9 service offering
Charles River Laboratories International, Inc. announced the expansion of its CRISPR/Cas9 service offering with the addition of a license from ERS Genomics Limited.
